About the Healthcare Industries Cluster
The Berlin-Brandenburg region is one of the leading life sciences and healthcare industries centers in the world. The region’s main strengths are its unique concentration of science, clinics and business and the close network they maintain. Numerous technology parks and networks in different fields, above all biotechnology and medical technology, create an ideal infrastructure for transforming the latest scientific findings into innovative products for the healthcare sector. The systematic innovation policy under the joint innovation strategy of the states Berlin and Brandenburg (innoBB) aims to expand the cluster's development and drive top performance for the regional and global healthcare markets.
The cluster managers welcome you to the HealthCapital cluster website!
Biotechnology and Pharmaceuticals
With cutting-edge research and development from molecules to products, biotechnology in the capital region provides an excellent environment for global players in the pharmaceuticals industry and top scientists.
World leaders in medical technology – many of the over 300 medical technology companies in Berlin-Brandenburg can claim this title. They benefit from the close network between science, business and clinics here.
Innovative Patient Care & Rehabilitation
For medical care and rehabilitation or nursing care – in the capital region, patients of all ages will benefit from capable, highly networked medical care at the highest level.
Health Tourism & Prevention
Berlin-Brandenburg is one of the most attractive healthcare regions with an international flair. It provides lots of space and a wide range of services for prevention, medical tourism and wellness.
The IT specialist for medicine, Professor Sylvia Thun, will be the new Director for eHealth and Interoperability at Berlin Institute of Health (BIH). The physician and qualified engineer is an expert in national and international...
MOLOGEN signs license deal for China and global co-development agreement with ONCOLOGIE for lead compound lefitolimod
MOLOGEN to receive a EUR 3 million initial payment as well as a EUR 2 million equity investment; Milestone payments of above EUR 100 million and double digit royalties on net sales; Strong support for global development program...
Research License Agreement on Unique Technology to Assess Drug Effects on the Immune System in Vitro.
Life Sciences Baltics 2018 is the only international forum in the Baltics for world-class biotechnology, pharmaceutical and medical devices experts from all around the world.
Natural & Nutraceutical Products China 2018
BIONNALE is the largest networking event for life sciences and healthcare industries in the German capital region.